Futura Medical plc (GYX.F)

0.4340 -0.0100 (-2.25%) As of 08:02AM CEST. Market open.

Futura Medical plc

Surrey Technology Centre
40 Occam Road
Guildford GU2 7YG
United Kingdom
44 14 8368 5670
https://www.futuramedical.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Henry Barder	CEO & Executive Director	552.38k	N/A	1959
Ms. Angela Hildreth	COO, Finance Director, Company Secretary & Executive Director	440.89k	N/A	1980
Mr. Kenneth William James	Head of R&D & Executive Director	404.68k	N/A	1952
Dr. William Duncan Potter	Chief Scientific Officer & Adviser to the Board	N/A	169.1k	1948
Graham Smith	Head of Alliance Partnerships & Supply	N/A	N/A	N/A
Kevin Langridge	Head of Quality	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health. Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Corporate governance

Futura Medical plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.